What is Conduit Pharmaceuticals Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Conduit Pharmaceuticals's annualizedGross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil.
Conduit Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2024 was $6.07 Mil. Therefore, Conduit Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.
Conduit Pharmaceuticals Gross-Profit-to-Asset % Historical Data
The historical data trend for Conduit Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Conduit Pharmaceuticals's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Conduit Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Conduit Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Conduit Pharmaceuticals's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Conduit Pharmaceuticals Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Conduit Pharmaceuticals (Conduit Pharmaceuticals) Business Description
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDT has been successfully added to your